共 50 条
- [41] Durable clinical outcomes in patients (pts) with advanced melanoma and progression-free survival (PFS) ≥3y on nivolumab (NIVO) ± ipilimumab (IPI) or IPI in checkmate 067JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Hodi, F. StephenChiarion-Sileni, VannaGonzalez, ReneGrob, Jean-JacquesRutkowski, PiotrLao, Christopher D.Cowey, Charles LanceSchadendorf, DirkWagstaff, JohnDummer, ReinhardQueirolo, PaolaSmylie, MichaelButler, Marcus O.Hill, Andrew GrahamMarquez-Rodas, IvanRitchings, CoreySakkal, Leon A.Wang, PeterWolchok, Jedd D.Larkin, James
- [42] FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volumeJOURNAL OF SURGICAL ONCOLOGY, 2001, 77 (04) : 237 - 242Wagner, JDSchauwecker, DSDavidson, DWenck, SJung, SHHutchins, G
- [43] Adjuvant nivolumab (NIVO) plus ipilimumab (IPI) for resected high-risk stages IIIC/IV melanoma (MEL).JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Khushalani, Nikhil I.Kim, YoungchulGibney, Geoffrey ThomasKudchadkar, Ragini ReineyEroglu, ZeynepMarkowitz, JosephCzupryn, Maria P.Thebeau, Melissa S.McCormick, LoriRichards, AllisonWeber, Jeffrey S.
- [44] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)Tawbi, Hussein Abdul-HassanForsyth, Peter A. J.Hodi, F. StephenLao, Christopher D.Moschos, Stergios J.Hamid, OmidAtkins, Michael B.Lewis, Karl D.Thomas, Reena ParadaGlaspy, John A.Jang, SekwonAlgazi, Alain PatrickKhushalani, Nikhil I.Postow, Michael A.Pavlick, Anna C.Ernstoff, Marc S.Reardon, David A.Balogh, AgnesRizzo, Jasmine I.Margolin, Kim Allyson
- [45] Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)ANNALS OF ONCOLOGY, 2019, 30 : 541 - 541Versluis, J. M.Reijers, I. L. M.Rozeman, E. A.van Akkooi, A. C. J.van Houdt, W. J.Bierman, C.van de Wiel, B. A.Long, G. V.Blank, C. U.
- [46] A PHASE I STUDY OF INTRALYMPHATIC (IL) ADMINISTRATION OF IPILIMUMAB (IPI) WITH INTRAVENOUS NIVOLUMAB (NIVO) USING THE SOFUSA® DOSECONNECT T DEVICE IN PATIENTS WITH ADVANCED MELANOMAJOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A817 - A817Dimou, AnastasiosSuman, VeraDenic, KristinaKottschade, LisaMontane, HeatherFinnes, HeidiFranta, KristinaSchimke, JillYan, YiyiMcWilliams, RobertBlock, MatthewJakub, JamesReid, JoelMarkovic, Svetomir
- [47] Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICOJOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 16 - 17Schadendorf, D.Ugurel, S.Eigentler, T.Mohr, P.Wei-Chenthal, M.Gebhardt, C.Goppner, D.Haferkamp, S.Herbst, R.Kahler, K.Kreuter, A.Meier, F.Pfohler, C.Sachse, M. M.Sickmann, T.Terheyden, P.Ulrich, J.Utikal, J. S.Grimmel-Mann, I.Gutzmer, R.
- [48] FDG-PET in the assessment of metabolic response in patients with NSCLC treated with nivolumab: Preliminary results.JOURNAL OF CLINICAL ONCOLOGY, 2017, 35Goldfarb, LucasDuchemann, BorisChouahnia, KaderGomez, LeaPop, GabrielZelek, LaurentSoussan, Michael
- [49] EFFICACY AND SAFETY IN KEY PATIENT SUBGROUPS OF NIVOLUMAB (NIVO) ALONE OR COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI ALONE IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CHECKMATE 067)Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 126 - 126Larkin, JamesChiarion-Sileni, VannaGonzalez, ReneGrob, Jean-JacquesCowey, C. LanceLao, Christopher D.Wagstaff, JohnHogg, DavidHill, AndrewCarlino, Matteo S.Wolter, PascalLebbe, CelesteSchachter, JacobThomas, LucHassal, Jessica C.Lorigan, PaulWalker, DanaJiang, JoelHodi, F. StephenWolchok, Jedd D.
- [50] Assessment of real-world effectiveness of first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) or NIVO monotherapy for advanced melanoma: A retrospective cohort studyANNALS OF ONCOLOGY, 2018, 29 : 457 - 457Freeman, M.Gupte-Singh, K.You, M.Le, T. K.Ritchings, C.Rao, S.Jang, S.